This agreement with Biogen is the most important news for Anavex since the 5 week results in the 2-73 Phase IIa showed a positive response.
Why? Validation, plain and simple. Like the validation of a 3rd party such as the Michael J. Fox Foundation studying A2-73.
But this is even bigger on a corporate level.
Third-Party interest changes everything. When that interest is one of the biggest, most respected biotechs in the world - it is a seismic shift in perception.
Almost certain the agreement with Biogen allows Biogen first dibs on negotiating rights to A2-73 for MS.
Anavex has publicly entered the big leagues today. Not to say there won't be volatility and bashing etc., but make no mistake that this is more significant on a corporate level than anything in perhaps the history of the company.
BP moves together. Others will be sniffing around.
Millstone